NCT06314659View on ClinicalTrials.gov

Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

630

Participants

Timeline

Start Date

September 17, 2021

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Healthy Population
Interventions
BIOLOGICAL

Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Zhifei Lvzhu)

Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months and booster immunization at 18 months of age.

BIOLOGICAL

Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Walvax)

Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months.

BIOLOGICAL

Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Olymvax)

Performed booster immunization at 18 months of age.

Trial Locations (1)

530028

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning

All Listed Sponsors
lead

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

INDUSTRY